The Rho-like GTPase, Rac1, induces cytoskeletal rearrangements required for cell migration. Rac activation is regulated through a number of mechanisms, including control of nucleotide exchange and hydrolysis, regulation of subcellular localization or modulation of protein-expression levels 1-3 . Here, we demonstrate that (the small ubiquitin-like modifier) SUMO E3-ligase, PIAS3, interacts with Rac1 and is required for increased Rac activation and optimal cell migration in response to hepatocyte growth factor (HGF) signalling. Rac1 can be conjugated to SUMO-1 in response to hepatocyte growth factor treatment and SUMOylation is enhanced by PIAS3. Furthermore, we identify non-consensus sites within the polybasic region of Rac1 as the main location for SUMO conjugation. PIAS3-mediated SUMOylation of Rac1 controls the levels of Rac1-GTP and the ability of Rac1 to stimulate lamellipodia, cell migration and invasion. The finding that a Ras superfamily member can be SUMOylated provides insights into the regulation of these critical mediators of cell behaviour. Our data reveal a role for SUMO in the regulation of cell migration and invasion.
To identify proteins that regulate Rac1 during cell migration, we performed tandem affinity purification (TAP) of native protein complexes containing TAP-tagged Rac1 from MDCKII (Madin-Darby canine kidney strain II) cells following HGF treatment (a ligand for the growth factor receptor c-Met, and a migration stimulus). The assay was performed at a time that Rac1 is activated and cells begin to migrate 4 ( Supplementary  Information, Fig. S1a-c) . Following TAP, protein complexes were analysed by mass spectrometry ( Supplementary Information, Fig. S1d and Table S1 ). Amongst known and putative Rac1 interactors, we identified PIAS3 (protein inhibitor of activated STAT3) as a Rac1-binding protein detected only in HGF-treated samples. PIAS3 interacts with Rac1 in vitro and in vivo (Fig. 1a, b and Supplementary Information, Fig. S1e , f) and this interaction was more efficient when Rac1 was in its activated form ( Fig. 1c and Supplementary Information, Fig. S1g ). Additionally, activation of HGF signalling using an oncogenic form of the Met receptor (Tpr-Met) 5, 6 increased this interaction ( Fig. 1d ).
Next, we examined if PIAS3 was necessary for cell migration in response to HGF. We generated stable MDCKII cell lines carrying doxycycline-inducible short hairpin interfering RNAs (shRNAs) to pias3 (two independent targets were used, labelled #1 and #2) or control scrambled-sequence shRNA ( Supplementary Information, Fig. S1h ). Downregulation of PIAS3 resulted in cells migrating slower than controls ( Fig. 1e ) and impaired lamellipodia-membrane ruffle formation ( Supplementary Information, Fig. S1i ). From the reduced migration and lamellipodia formation, we hypothesized that PIAS3 might be influencing Rac-GTP levels. Significantly, although Rac-GTP levels increased in control cells following HGF treatment, no increase was observed in PIAS3-downregulated cells, despite normal activation of the ERK MAPK pathway, indicating a specific requirement of PIAS3 for Rac activation (Fig. 1f ). Consistent with this defect in Rac activation, phosphorylation (and hence activation) of p38, a known downstream mediator of Rac signalling 7 , was impaired in PIAS3-downregulated cells ( Supplementary  Information, Fig. S1j ). HGF stimulates the motility of epithelial cells by initially inducing the spread of cell colonies through lamellipodia-membrane ruffle formation, followed by disruption of cell-cell junctions and subsequent cell scattering; Rac1 is involved in both processes 8 . PIAS3 was required not only for optimal initial Rac activation following HGF treatment, but also for optimal Rac activation at later times (Fig. 1g ). This continuous involvement of PIAS3 in Rac activation could explain the defect in migration observed throughout the 24 h of HGF treatment. Rac-GTP levels were elevated in cells overexpressing PIAS3 and also treated with HGF, compared with control cells (Fig. 1h, i) , confirming a function for PIAS3 in augmenting Rac-GTP levels following HGF treatment. In addition to HGF, the modest activation of Rac by epidermal growth factor (EGF), or serum, was also impaired in PIAS3-downregulated cells ( Supplementary Information, Fig. S1k and data not shown). This indicates that the requirement of PIAS3 for optimal Rac activation is not restricted to a particular upstream stimulus. However, downregulation of PIAS3 did not affect Cdc42-GTP levels ( Supplementary Information,  Fig. S1l ). These data indicate that PIAS3 is required for the induction, or more probably the maintenance, of Rac activation following growth factor treatment, as the Rac-PIAS3 interaction is stronger for Rac-GTP when compared with Rac-GDP, or for Rac1V12 (constitutively activated Rac1) when compared with wild-type Rac1. PIAS3 is therefore required for optimal cell migration.
Most reported PIAS3 substrates are nuclear proteins, frequently transcription factors 9, 10 , although PIAS3 has also been detected in the cytoplasm. In contrast, Rac is mainly cytoplasmic, although nuclear Rac has been reported 11, 12 . To identify whether PIAS3 regulates Rac activation in the cytoplasm, we used a truncated version of PIAS3, CPIAS3, that is exclusively nuclear (Fig. 2a, b) 13 . In contrast to overexpression of full-length PIAS3, overexpression of CPIAS3 did not increase Rac-GTP levels in response to HGF treatment ( Fig. 2c, d) , even though Rac1 interacts with CPIAS3 in vitro and in vivo ( Supplementary Information,  Fig. S2a-c) . Furthermore, PIAS3 co-localizes with Rac1 in the leading edge of cells and translocates from the cytosol to the membrane in response to HGF ( Supplementary Information, Fig. S2d, e ). These results suggest that PIAS3 regulates Rac activation in the cytoplasm, and most probably at sites of membrane protrusion. 
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Rac activation (fold increase) Figure 1 PIAS3 is a Rac1-binding protein required for optimal Rac activation and cell migration in response to HGF treatment. (a) GST protein or GST-Rac1 were incubated with cell extracts from cells expressing Flag-PIAS3, and GST pulldowns were analysed by western blot. (b) Epitope-tagged proteins were expressed in HEK293T cells and GFP immunoprecipitation was performed. Purified proteins were detected by western blot. (c) GST-Rac1 beads divided into two samples were incubated with GDP or γGTP and then with equal amounts of cell lysate containing Flag-PIAS3. PIAS3 interaction was detected by western blot. Fold-change represents increase in band intensity for γGTP treatment, compared with GDP treatment. (d) HEK293T cells were transfected with plasmids expressing the indicated proteins, and subjected to immunoprecipitation with anti-GFP. Samples were analysed by western blot. (e) Cells were treated with doxycycline to induce control scrambled-sequence shRNA or shRNA specific to pias3 (two independent targets, #1 and #2 PIAS proteins function as SUMO E3-ligases 10 . SUMOylation is a covalent modification leading to the attachment of SUMO to specific lysine residues of target proteins 14 . In vitro SUMOylation followed by western blotting revealed a band consistent with the attachment of SUMO-1 (S1) or SUMO-2/3 (S2/S3) to Rac1, which was absent when E1, E2 or SUMO protein was not present (Fig. 3a ). Furthermore, SUMOylation was enhanced by increasing the E2-conjugating enzyme Ubc9 ( Supplementary Information, Fig. S2f ). In most cases, SUMOylation of a substrate is enhanced by a SUMO E3-ligase 10, 15 . Rac1 SUMOylation was enhanced by increasing amounts of PIAS3 ( Supplementary Information, Fig. S2g ). Other PIAS family members also enhanced in vitro Rac1 SUMOylation, although PIAS3 was the most efficient ( Supplementary Information, Fig. S2g ). Additionally, in vitro SUMOylation of GFP-Rac1 immunoprecipitated from HeLa cells was enhanced upon co-transfection of Flag-PIAS3 ( Fig. 3b ). Conversely, downregulation of PIAS3 decreased in vitro SUMOylation of GFP-Rac1 ( Supplementary Information, Fig. S2h ). These results indicate that PIAS3 functions as a SUMO E3-ligase for Rac1. Furthermore, consistent with the finding that PIAS3 binds more efficiently to GTP-bound Rac1 ( Fig. 1c and Supplementary Information, Fig. S1g ), Rac1V12 had higher SUMOylation, compared with wild-type Rac1 (Fig. 3c ).
Next, we evaluated whether Rac1 could be SUMOylated in vivo. SUMOylation is reversed by the SUMO-specific proteases SENP1-3 and SENP5-7 (ref. 16) . Therefore, N-ethylmaleimide (NEM) was added to the lysis buffer to inhibit these SUMO-deconjugating enzymes 17 . This resulted in detection of higher molecular weight Rac1 bands that potentially represent SUMO-modified Rac1 from cells co-expressing 6His-SUMO-1 and GFP-Rac1 ( Supplementary Information, Fig. S2i ). To further demonstrate in vivo SUMOylation of Rac1, TAP-Rac1 was expressed with GFP-SUMO-1 or a GFP-SUMO-1 mutant that lacks the diglycine carboxy-terminal motif required for its conjugation to substrates (GFP-SUMO-1 ΔGG ). Probing GFP immunoprecipitates for Rac revealed up to three bands in lysates from GFP-SUMO-1-, but not GFP-SUMO-1 ∆GG -expressing cells ( Fig. 3d ). Furthermore, incubation of these GFP immunoprecipitates with the active domain of SENP1 (ref. 18 ) resulted in loss of the higher-molecular-weight bands ( Fig. 3e ), confirming that these represented SUMO conjugates. As SUMO-1 is not thought to form polymeric chains in vivo 19 , the presence of multiple bands suggested that Rac1 could be SUMOylated at multiple sites.
As PIAS3 was identified as a Rac interactor in response to HGF treatment, we analysed if activation of the Met-HGF pathway induced the appearance of endogenous Rac1-SUMO-1 conjugates. Endogenous Rac1-SUMO conjugates were visualized in HeLa cells stably expressing 6His-SUMO-1 (ref. 20) following only transfection with Tpr-Met ( Fig. 3f ). Furthermore, we detected co-localisation of endogenous SUMO-1 and endogenous Rac1 in membrane ruffles of HGF-treated MDCKII cells ( Supplementary Information, Fig. S3a ). To visualize SUMOylation of endogenous Rac1 by addition of HGF alone, and to determine the role of PIAS3 in this process, MDCKII cells were treated with HGF in the presence of a chemical cross-linker (DSS; disuccinimidyl suberate). This preserved SUMO-conjugated Rac during immunoprecipitation with a Rac-GTP-specific antibody or during CRIB-pulldown of GTP-Rac. Endogenous GTP-Rac1-SUMO-1 was detected in control cells following HGF treatment, but not in PIAS3 downregulated cells ( Fig. 3g and Supplementary Information, Fig. S3b ). We next determined whether SUMOylation of endogenous Rac occurs under other conditions that induce Rac activation. Calcium-switch stimulates cell-cell adhesion in confluent epithelial cells and Rac1 activation 21 . Following calcium readdition and endogenous Rac-GTP pulldown, endogenous Rac1-SUMO conjugates were detected ( Fig. 3h ). Quantification of SUMO-conjugated and unmodified Rac-GTP indicated that the SUMO-modified fraction is a significant proportion of Rac-GTP (Fig. 3h, bottom) .
Frequently, SUMO targets the consensus sequence ΨKXD/E, where Ψ represents a hydrophobic residue and K the acceptor-residue, lysine, but non-consensus sites have also been reported 22, 23 . As Rac1 lacks a consensus motif, we adopted a mass spectrometry approach to identify SUMO-modified site(s). GST-Rac1 was in vitro SUMOylated, the band corresponding to GST-Rac1-SUMO-1 ( Fig. 4a ) was subjected to in-gel trypsin digestion and branched peptides were then identified by mass spectrometry. MaxQuant 24 was used for label-free Rac activation (fold increase)
Rac1 is SUMOylated in vitro and in vivo. (a) GST-Rac1 protein was incubated at 37 °C in vitro in the presence of complete SUMOylation assay components (E1, E2, SUMO-1; S1, or SUMO-2; S2) and resolved by SDS-PAGE. Unmodified sample (Um) contains all the assay components but without incubation at 37 °C. Rac1-S1/Rac1-S2 indicates Rac1 modified by SUMO-1 or SUMO-2. (b) GFP-Rac1 was immunoprecipitated from HeLa cells in the presence or absence of PIAS3 and in vitro SUMOylation assay was performed, as indicated. Rac1 was detected by western blot. Foldchange represents increase in band intensity of SUMOylated GFP-Rac1 in presence of Flag-PIAS3, compared with SUMOylated GFP-Rac1 in absence of Flag-PIAS3. (c) Immunoprecipitated GFP-Rac1 or GFP-Rac1V12 was subjected to in vitro SUMOylation as indicated and Rac1 was detected by western blot. Fold-change represents increase in band intensity for SUMOylated GFP-Rac1V12, compared with SUMOylated GFP-Rac1. (d) HeLa cells, transfected as indicated, were lysed in the presence of NEM, and GFP was immunoprecipitated. The presence in immunoprecipitates of exogenous Rac1 or GFP was detected by western blot. (e) GFP-SUMO-1 was immunoprecipitated from HeLa cells (transfected as indicated), divided into two and incubated in the presence or absence of SENP1. (f) HeLa cells stably expressing 6His-SUMO-1 were transfected with Tpr-Met , and 6His-SUMO-1-modified proteins were purified from lysates. Endogenous Rac1-SUMO-1 was detected by western blot. (g) MDCKII cells stably expressing control shRNA or pias3 shRNA were treated with HGF as indicated, in the presence of the crosslinker DSS, and Rac-GTP immunoprecipitation was performed. GTP-Rac1-SUMO-1 bands were detected by western blot. (h) MDCKII cells were grown to confluency and incubated in low calcium medium. Rac activation was measured after calcium re-addition for the indicated times. Pulldowns of activated Rac were analysed by western blot for Rac and SUMO-1. Blots at the bottom represent part of the top blot and show the unmodified Rac-GTP band at lower exposure, and levels of total Rac. Quantification of the Rac-GTP bands, both SUMO-modified and unmodified, are represented in the histogram, normalized to total Rac. Rac-nS1 in (b-h) is multi-mono-SUMOylated Rac1. Uncropped images of blots are shown in Supplementary Information, Fig. S6 . approximate quantification of the relative abundance of branched peptides. Although 10 of the potential total 17 Lys-SUMO-1 branched peptides were identified, almost 95% of the SUMO-1 modified Rac1 was conjugated at Lys 188, 183 and 184 or 186 ( Fig. 4b ) present within the C-terminal polybasic region (PBR) of Rac1 ( Fig. 4c ).
Replacement of the putative SUMOylation lysine residues with arginine residues (same charge) within the PBR abolished most of the Rac1 SUMOylation in vitro ( Supplementary Information, Fig. S3c-e ). Furthermore, Lys 96, 123, 130, 132 and 133 were not confirmed as SUMO-sites ( Supplementary Information, Fig. S3f and data not shown). 
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Anti-GFP Anti-GFP Interestingly, the in vitro SUMOylation assay showed one SUMO-Rac1 band, but mass-spectrometry analysis identified more than one lysine modified by SUMO-1. This suggests that SUMOylation can occur on any of the lysines within the PBR. The monomeric SUMOylation of Rac1 in vitro is in contrast to the multiple SUMO-conjugate bands detected in vivo, presumably resulting from multi-monoSUMOylation. This difference implies the existence of additional factors in vivo that support multi-monoSUMOylation.
To confirm that the lysines present in the PBR were SUMOylated in vivo we generated a GFP-Rac1 mutant in which the four lysines of the PBR were replaced with arginines (GFP-Rac1 ∆SUMO ; Fig. 4c ). The Rac1 ∆SUMO mutation was sufficient to decrease Rac1 SUMOylation ( Fig. 4d ), but not ubiquitylation ( Fig. 4e and Supplementary  Information, Fig. S3g ). The PBR of Rac1 is implicated in binding certain effectors [25] [26] [27] , as well as plasma membrane, and nuclear localization 11, 28, 29 . The Rac1 ∆SUMO mutation did not disrupt membrane, or nuclear, localization of Rac ( Supplementary Information, Fig. S4a -c), nor did it affect Rac interaction with PIAS3, the effector IQGAP, or the guanine nucleotide exchange factors (GEFs), β-Pix and Tiam1 ( Supplementary  Information, Fig. S4d-g) .
Fraction of positive cells with lamellipodia or membrane ruf es Next, we investigated the connection between Rac1-GTP levels and SUMO modification. Interestingly, GFP-Rac1 ∆SUMO bound less GTP than wild type ( Fig. 4f ), suggesting that Rac SUMOylation was required to increase or maintain its activation. Consistently, a Rac1 chimaera that mimics constitutive SUMOylation (GFP-SUMO-1-Rac1; Supplementary Information, Fig. S4h ) bound more GTP than wild-type Rac1 (Fig. 4g ). Furthermore, GFP-SUMO-1-Rac1 was localized similarly to wild-type GFP-Rac1 ( Supplementary Information, Fig. S4i, j) . These results suggest that Rac1 SUMOylation is not necessary for Rac1 localization, but is required for optimal GTP loading.
Subsequently, we addressed whether the defect in activation of non-SUMOylated mutant Rac affects its ability to promote cell migration. Rac1-null mouse embryonic fibroblasts (MEFs) derived from Rac1 conditional knockout mice are unable to form lamellipodia-membrane ruffles and are defective in cell migration ( Supplementary Information,  Fig. S5a and ref. 30 ). We detected a higher-molecular weight Rac1 in wild-type MEFs that potentially corresponds to Rac1-SUMO-1 ( Supplementary Information, Fig. S5b ). Rac1-depleted MEFs were transfected with plasmids expressing GFP, wild-type GFP-Rac1 or GFP-Rac1 ∆SUMO (Fig. 5a ) and GFP-positive cells were analysed for the presence of lamellipodia-membrane ruffles (Fig. 5b) . Whereas wild-type Rac1 rescued the lamellipodia-ruffle formation to around 85% of wildtype levels, non-SUMOylated Rac1 restored it to only 45% (Fig. 5c ). Furthermore, unlike wild-type Rac1, the ∆SUMO mutant was unable to rescue the migration defect ( Fig. 5d and Supplementary Information,  Fig. S5c ), or impaired invasiveness, of Rac1-depleted cells ( Fig. 5e ; see also Supplementary Information, Fig. S5d where the induction of invasion by HGF is demonstrated). However, the ∆SUMO mutant was equally competent as wild-type Rac1 in rescuing the clonogenic defect of Rac1-depleted MEFs ( Supplementary Information, Fig. S5e, f) .
Similarly to MDCKII, PIAS3 downregulation in MEFs resulted in reduced migration and membrane-ruffle formation ( Supplementary  Information, Fig. S5g and data not shown). To determine whether PIAS3 was required for the ability of wild-type Rac1 to rescue cell migration in Rac1-depleted cells, PIAS3 was downregulated and cells were transduced with vectors to express wild-type GFP-Rac1 (Fig. 5f ), before being analysed for migration and membrane-ruffle formation. Significantly, although wild-type Rac1 partly restored the migration and membrane ruffling of Rac1-depleted cells additionally expressing control shRNA, it was unable to do so in cells expressing shRNA targeting pias3 ( Fig. 5g and Supplementary Information, Fig. S5h ). These results suggest that PIAS3, probably through promotion of Rac SUMOylation, is to a great extent responsible for the ability of wild-type Rac1 to rescue the phenotype of the Rac1-depleted cells. However, it cannot be excluded that PIAS3 exerts some Rac-independent effects on cell motility.
Our study demonstrates that Rac1, and particularly GTP-bound Rac, can be SUMOylated. Although SUMOylated-Rac represents a small fraction of total Rac, it can be a significant fraction of GTP-bound Rac (Fig. 3g, h) . However, not all Rac-GTP is SUMOylated (Fig. 3g, h) , and Rac1 ΔSUMO retained some GTP-binding ( Fig. 4f) . Also, PIAS3 interacts more with Rac-GTP than Rac-GDP (Fig. 1c) , and activated Rac1 is a better SUMOylation substrate than wild-type Rac1 (Fig. 3c) . Therefore, the data indicate that SUMOylation is not essential for activation, but rather influences the maintenance of the activated state. Consistent with this, levels of activated Rac1 following HGF treatment were reduced by downregulation of PIAS3 ( Fig. 1f and 3g) , and augmented by PIAS3 overexpression (Figs 1h, i and 2c, d) , mirroring the effects of PIAS3 on levels of Rac SUMOylation (Figs 3b, g and Supplementary Information, Figs S2h and S3b). Furthermore, a SUMO-mimicking Rac1 chimaera bound more GTP than wild-type Rac1 (Fig. 4g ). Potentially, Rac SUMOylation could either increase its binding to a GEF, or conversely decrease binding to a GTPase-activating protein (although such effects need to be demonstrated; for model see Supplementary Information,  Fig. S5i ). Significantly, we demonstrate that Rac SUMOylation is important for optimal lamellipodia-ruffle formation, cell migration and invasion ( Fig. 5b-e ), but not for clonogenicity ( Supplementary Information,  Fig. S5e, f) . This conclusion is strengthened by the observation that PIAS3 is required for wild-type Rac1 to restore membrane ruffling and migration in Rac1-depleted MEFs (Fig. 5g ). SUMOylation might increase activated Rac levels above a threshold required for lamellipodia formation, cell migration and invasion and/or target a pool of Rac towards particular biological functions through influencing binding to effector molecules, consistent with findings that SUMOylation of other proteins influences their interactions 31 . Overall, our study advances our understanding of how GTPases, and in turn cell migration, are regulated, and could provide new targets for future therapeutic intervention.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/ DOI: 10.1038/ncb2112 METHODS Constructs. Amino-terminal TAP tag (N-TAP) cloned in pcDNA4/TO (Invitrogen) was a gift from H. Clevers (Hubrecht Laboratory, The Netherlands). Mouse full-length Rac1V12 was cloned in-frame with N-TAP (to yield TAP-Rac1V12). This was used as a template to mutate Val 12 to Gly 12 using the QuickChange site-directed mutagenesis kit (Stratagene). A mammalian expression construct encoding wild-type PIAS3 (Myc-PIAS3) was provided by H. Yokosawa (Hokkaido University, Japan). The Tpr-Met plasmid was provided by L. Trusolino (Institute for Cancer Research and Treatment, Italy). Flag-PIAS3 was obtained by cloning pias3 cDNA in-frame with the Flag-epitope tag of pGloFlag vector provided by A. Hurlstone (University of Manchester, UK). Full-length pias3 was fused to the N-terminus of the glutathione S-transferase (GST) gene in pGEX-KG. GST-NPIAS3 and GST-CPIAS3 were obtained by replacing fulllength pias3 with the first 900 or last 981 bases, respectively, of pias3. Myc-CPIAS3 was obtained by replacing full-length pias3 cDNA in the Myc-PIAS3 plasmid with the last 981 bases of pias3. Wild-type GFP-Rac1 and GFP-SUMO-1 were obtained by cloning wild-type Rac1 or SUMO-1, respectively, into pEGFP-C1 (Clontech). The mutant GFP-SUMO-1 ΔGG was obtained by deleting the last six amino acids from the C-terminus of GFP-SUMO-1. The GFP-SUMO-1 ∆GG -Rac1 plasmid was obtained by cloning SUMO-1 ∆GG into the GFP-Rac1 plasmid. GST-Rac1 ∆SUMO-1 , GST-Rac1 2KRa, 2KRb, 3KRa, 3KRb or GFP-Rac1 ∆SUMO-1 mutants were derived from wild-type GST-Rac1 or wild-type GFP-Rac1, respectively, using site-directed mutagenesis. The generation of the single-vector tetracyclinerepressor based inducible shRNA system has been described elsewhere 32 . DNA sense and antisense oligonucleotides were generated against the following target sequences in pias3: shRNA#1, 5ʹ-CCAACACCATCGTGGTCAA-3ʹ; shRNA #2, 5ʹ-CCTTCCTCCTACCAAGAAT-3ʹ. pRS-PIAS3 shRNA was generated by cloning shRNA#1 into pRETROSUPER.
Cell culture and cell lines. HEK293T, MDCKII, HeLa and COS7 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen) in the presence of 10% fetal bovine serum (FBS; GIBCO). MEF Rac1 +/+ cells, a gift from L. Vidali (University of Massachusetts, USA), were maintained in the same medium containing 70 μM β-mercaptoethanol. Rac1 deletion was induced by incubating cells with Ad5CMCre-eGFP (Gene Transfer Vector Core; University of Iowa). Cell lines expressing the inducible shRNA system were maintained in DMEM supplemented with 10% tetracycline-free FBS (Autogen Bioclear) and 1 mg ml -1 G418 (Sigma). HEK293T, HeLa and COS7 cells were transfected using Fugene 6 (Roche). Single cell clones of MDCKII cells stably expressing TAP-tagged wild-type Rac1 or N-TAP were used for subsequent experiments. For growth factor treatment, serum was removed for 18 h before addition of 10 ng ml -1 HGF or EGF (R&D Systems) for 30 min, or as indicated. COS7 cells were transfected in the presence of 10% FBS and left for 24 h before serum removal and growth factor treatment. For the calcium-switch experiment, MDCKII cells were grown to confluency in complete medium, after which medium was changed to low calcium (0.02 mM) for 18 h. Calcium containing medium (1.8 mM) was added back for the indicated times. For PIAS3 downregulation, MDCKII cells with pias3 or control shRNAs were treated with 1 μg μl -1 doxycycline (dox) for 4 days. For the cross-linking of Rac1-SUMO conjugates in vivo a range of DSS concentrations were added (Thermo Scientific) in the presence of HGF for 30 min. The reaction was quenched by addition of glycine to a final concentration of 20 mM for 15 min. Cells were washed twice in ice-cold PBS and subjected to either Rac-GTP pulldown assay or immunoprecipitation with anti-activated Rac-GTP antibody (NewEast Biosciences). For SENP1 treatment, immunoprecipitates were treated for 2 h at 25 o C. TAP purification. MDCKII cells stably expressing TAP-Rac1 or N-TAP were plated at low density in five 500 cm 2 plates and allowed to grow in small colonies. Serum was removed for 18 h before the addition of 10 ng ml -1 HGF. TAP purification was performed as previously described 33 .
GST pulldowns. GST pulldowns were performed as previously described 34 . For Figure 1e , GST-Rac1 beads were incubated with GDP or γGTP for 1 h at 30 °C, and then with equal amounts of cell lysate containing Flag-PIAS3 for 1 h at 4 °C.
Nickel affinity purification. 6His-SUMO-1 or 6His-Ubiquitin-binding proteins were purified from cell lysates using nickel-nitrilotriacetic acid agarose (QIAGEN) as previously described 35 .
Protein analysis. For immunoprecipitation and immunoblot analysis, cell lysates were prepared in immunoprecipitation lysis buffer (50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 2 mM EDTA, 25 mM NaF and 2 mM NaH 2 PO 4 ) containing protease and phosphatase inhibitor cocktails (Sigma). Equivalent amounts of protein were either denatured with SDS-PAGE sample buffer (Nupage, Invitrogen) for immunoblotting, or incubated with 2-5 μg antibody pre-bound to 20 μl of GammaBind G-Sepharose (Amersham) for immunoprecipitation analysis. Immunoprecipitated proteins were eluted with SDS-PAGE sample buffer (Nupage, Invitrogen), resolved by SDS-PAGE, and transferred to polyvinylidene difluoride membrane (Immobilon-P; Millipore). Immunoblotting was performed using the following primary antibodies: anti-Myc (1:5,000; Clone 9E10, CRUK), anti-Flag (1:10,000; Clone M2, Sigma), anti-Rac (1:1,000; clone 102, BD Biosciences), anti-Rac1 (1:1,000; ARC03, Cytoskeleton), anti-Cdc42 (1:1,000; Santa Cruz), anti-Rho GDI (1:5,000; Clone A-20, Santa Cruz), anti-IQGAP1/2 (1:5,000; Clone 24, BD Biosciences), anti-GST (1:10,000; ab58626, Abcam), anti-PIAS3 (1:1,000; N-Term or C-Term, ABGENT), anti-PAP (1:5,000; p 1291, Sigma), anti-c-Met (1:5,000; Clone C-12, Santa Cruz), anti-Tubulin (1:10,000; Clone TAT-1, CRUK), anti-GFP (1:5,000; CRUK), anti-6His (1:10,000; 631212, Clontech), anti-Tiam1 (1:1,000; C16, Santa Cruz), anti β-Pix (1:1,000; BD Biosciences), anti-ERK (1:2,000; Cell Signaling), anti-p-ERK (1:2,000; Cell Signaling), anti-p-p38 (1:1,000), anti-p38 (1:1,000; Cell Signaling), and subsequently with horseradish peroxidise-conjugated anti-mouse, anti-rabbit or anti-sheep secondary antibodies (1:5,000; GE Healthcare) and visualised by enhanced chemiluminescence (Perkin Elmer).
Subcellular fractionation.
Cells were washed and treated with ice-cold hypotonic lysis buffer (10 mM Tris-HCl at pH 7.4, 1.5 mM magnesium chloride, 5 mM potassium chloride, 1 mM DTT, 0.2 mM sodium vanadate, 1 mM PMSF; phenylmethanesulfonylfluoride) containing protease and phoshatase inhibitor cocktails (Sigma) for 5 min. Lysates were homogenized by sonication at low speed. Homogenates were centrifuged at 700g for 3 min to pellet nuclei and intact cells. Supernatants were then spun at 40,000g for 30 min at 4 o C. The cytosol-containing supernatant was removed and the crude membrane pellet gently washed with hypotonic lysis buffer. Equal amounts of protein from membrane and cytosol fractions were then analysed by western blotting.
In vitro SUMOylation. In vitro SUMOylation reactions contained E1 enzyme (250 ng SAE1/SAE2), E2 enzyme (1.2 μg Ubc9), SUMO-1 or SUMO-2 protein (5.7 μg) and GST-Rac1 protein (5 μg) in SUMOylation buffer (55 mM Tris at pH 7.5, 5.5 mM MgCl 2 , 2.2 mM ATP, 5.5 mM DTT; dithiothreitol). SUMOylation reactions were incubated at 37 o C for 4 h. After termination with SDS-PAGE sample buffer, reaction products were separated on SDS-PAGE.
Rac and Cdc42 activation. Rac and Cdc42 activity assays were performed as previously described 33 .
Cell migration assay. MDCK cells stably expressing pias3 shRNAs were plated in the presence or absence of doxycycline for 4 days. Cells were seeded sparsely and images were acquired every 30 min for 24 h at 37 o C using a time-lapse system consisting of a Zeiss Axiovert 200M microscope under the control of Metamorph software (Molecular Devices). Single cells were manually tracked using ImageJ software (NIH).
Invasion assay. Cells were suspended in serum-free collagen I at 2.3 mg ml -1 to a final concentration of 10 5 cells ml -1 and HGF (10 ng ml -1 ) was added where indicated. Aliquots (100 μl) were dispensed into 96-well ViewPlates (Perkin-Elmer) coated with 0.2% bovine serum albumin (Sigma). Plates were centrifuged at 300g (to sediment cells) and incubated at 37 o C and 5% CO 2 for 60 min before adding 30 μl of DMEM (Invitrogen) containing 10% FBS (GIBCO) and β-Mercaptoethanol. After 24 h, cells were fixed in 4% formaldehyde and stained with 5 mg ml -1 Hoechst 33258 (Sigma). Confocal z sections were collected from each well at 0 μm (bottom of the well) and 40 μm with a BD Pathway bioimager 855 High Content Screening System. Nuclear staining was quantified with ATTovision software (BD; version 1.61855). Invasion indexes were calculated as the number of cells at 40 μm divided by those at 0 μm (mean values of quintuplicate samples).
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M E T H O D S
Identification of proteins from TAP by liquid chromatography-mass spectrometry (LC-MS/MS) analysis and database searches.
Gel lanes from onedimensional (1D) gels (Nupage 4−12%) were manually cut into 40 × 1.5 mm bands using a razor blade. Processing of bands and mass spectrometry analysis was performed as previously described 33 . Product ion data were searched against the combined forward and reverse Canis familiaris protein database build 2.1 downloaded from NCBI RefSeq (ftp://ftp.ncbi.nih.gov/genomes/Canis_familiaris/) using the same criteria as previously described 33 . These criteria resulted in a false discovery rate (FDR) of 0.5% at the protein level for this data set. Of these identified proteins, only those that were detected in TAP-Rac1 samples in three different experiments, and not in control N-TAP samples, were classified as being Rac1-specific interactors.
Identification of sites of Rac1 sumoylation in vitro.
GST-Rac1 was modified with SUMO-1 by in vitro conjugation. Assay components were fractionated by SDS-PAGE and Coomassie-stained protein bands subjected to in-gel digestion with trypsin (Promega) as described previously 36 . Mass spectrometric analysis was performed by LC-MS/MS using a linear ion trap-orbitrap hybrid mass spectrometer (LTQ-Orbitrap, Thermo Fisher Scientific) equipped with a nanoelectrospray ion source and coupled to a Proxeon nano-HPLC system (Proxeon Biosystems). Peptides were injected into a 150 mm reverse phase C 18 column and eluted with a linear 60-min gradient. Data were acquired in the data-dependent mode to automatically switch between MS and MS/MS acquisition. The five most intense ions with 3+ or greater charge were fragmented by collision induced dissociation and recorded in the linear ion trap.
Mass spectrometry raw data files were processed using the quantitative mass spectrometry processing software MaxQuant (version 1.0.12.31; ref. 36 ) with SILAC type set to 'singlets' 37, 38 , and using the Mascot search engine (Matrix Science, version 2.2.2). Enzyme specificity was set to trypsin-P. Cysteine carbamidomethylation was selected as a fixed modification and methionine oxidation and protein N-acetylation were searched as variable modifications. Data were searched against a target/decoy human IPI database (version 3.24) 39 that was appended with linear mimetics of branched peptides representing all possible lysine modifications of Rac1 with the C-terminal tryptic fragment of SUMO-1. The use of linear representations of branched adducts has already been described for automated database search applications 40 . By this method, identified branched peptides are shortlisted as proteins in the MaxQuant output file. Initial maximum-allowed mass deviation was set to 7 parts per million (ppm) for peptide masses and 0.5 Da for MS/MS peaks. The minimum peptide length was set to six amino acids and a maximum of four missed cleavages. 1% false discovery rate (FDR) was required at both the protein and peptide level. respectively. (f) GST-Rac1 protein was incubated at 37 o C with E1, S1 and an increasing amount of Ubc9 (E2). Rac1 was detected by WB. (g) GST-Rac1 protein was incubated with E1, E2, and S1 together with increasing amounts of recombinant members of the PIAS family or RanBP2 (another SUMO E3ligase). Rac1 was detected by WB. (h) GFP-Rac1 was immunoprecipitated from HeLa cells in the presence or absence of pias3 shRNA and in vitro SUMOylation performed as in (f). Rac1 was detected by WB. (i) HeLa cells stably expressing 6His-SUMO-1 were transfected with either GFP or GFP-Rac1. Cells were lysed in the presence of NEM and GFP was immunoprecipitated followed by WB for Rac. GFP-Rac1 immunoprecipitates in the presence of NEM show the presence of three specific Rac1 bands corresponding to SUMOylated Rac. Rac1-nS1 indicates Rac1 modified by SUMO-1. Consequently, Rac1 remains longer in its GTP-bound form (perhaps because it is localized by SUMO-1 to an environment free from GAPs or because SUMO-1 antagonizes GAP binding). Thus, SUMOylation results in stabilization of a pool of GTP-bound Rac1 which promotes membrane protrusion and cell migration. SENPs deSUMOylate Rac1, so that it becomes a substrate once more for GAPs. 
